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Abstract
Background: Red bone marrow (RBM) toxicity is dose-limiting in (pretargeted)
radioimmunotherapy (RIT). Previous blood-based and two-dimensional (2D)
image-based methods have failed to show a clear dose-response relationship. We
developed a three-dimensional (3D) image-based RBM dosimetry approach using the
Monte Carlo-based 3D radiobiological dosimetry (3D-RD) software and determined
its additional value for predicting RBM toxicity.
Methods: RBM doses were calculated for 13 colorectal cancer patients after
pretargeted RIT with the two-step administration of an anti-CEA × anti-HSG bispecific
monoclonal antibody and a 177Lu-labeled di-HSG-peptide. 3D-RD RBM dosimetry was
based on the lumbar vertebrae, delineated on single photon emission computed
tomography (SPECT) scans acquired directly, 3, 24, and 72 h after 177Lu administration.
RBM doses were correlated to hematologic effects, according to NCI-CTC v3 and
compared with conventional 2D cranium-based and blood-based dosimetry results.
Tumor doses were calculated with 3D-RD, which has not been possible with 2D
dosimetry. Tumor-to-RBM dose ratios were calculated and compared for 177Lu-based
pretargeted RIT and simulated pretargeted RIT with 90Y.
Results: 3D-RD RBM doses of all seven patients who developed thrombocytopenia
were higher (range 0.43 to 0.97 Gy) than that of the six patients without
thrombocytopenia (range 0.12 to 0.39 Gy), except in one patient (0.47 Gy) without
thrombocytopenia but with grade 2 leucopenia. Blood and 2D image-based RBM doses
for patients with grade 1 to 2 thrombocytopenia were in the same range as in patients
without thrombocytopenia (0.14 to 0.29 and 0.11 to 0.26 Gy, respectively). Blood-based
RBM doses for two grade 3 to 4 patients were higher (0.66 and 0.51 Gy, respectively)
than the others, and the cranium-based dose of only the grade 4 patient was higher
(0.34 Gy). Tumor-to-RBM dose ratios would increase by 25% on average when treating
with 90Y instead of 177Lu.
Conclusions: 3D dosimetry identifies patients at risk of developing any grade of RBM
toxicity more accurately than blood- or 2D image-based methods. It has the added
value to enable calculation of tumor-to-RBM dose ratios.
© 2014 Woliner-van der Weg et al.; licensee Springer. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited.
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Background
The aim of radioimmunotherapy (RIT) is to selectively target radioactivity to tumor le-
sions, with limited radiation dose to healthy tissues. The absorbed dose (AD) depends
on the patient-specific pharmacokinetics of the tracer, the administered activity, and
the radionuclide. After pre-therapeutic administration of a diagnostic-labeled com-
pound, dosimetric calculations (matched pair dosimetry) lead to a patient-specific
insight into how best to treat the patient. For example, pre-treatment dosimetry can be
used to adjust the individual therapy dose, or even be used to select the most suitable
radionuclide for therapy. Ideally, this will lead to an improved benefit-versus-risk ratio
for individual patients.
In external beam radiotherapy, patient-specific treatment planning is a common prac-
tice because treatment planning is based on absorbed dose distributions and dose-
response relationships for both tumor and normal tissues are relatively well known.
However, for RIT, dose-response relationships have not been rigorously established and
dose estimation has been less accurate and focused on calculating mean absorbed
doses. In radionuclide therapy, the mean absorbed dose may not be useful for predict-
ing tumor response and, in some cases, for predicting normal organ toxicity. Therefore,
further investigation of dose-response relationships and development of dosimetry
methods that provide dose-volume histograms and that incorporate radiobiological
modeling for the clinical practice of radioimmunotherapy are highly desirable.
Since the red bone marrow (RBM) is often dose-limiting in RIT [1-6], the focus of
the present study was on RBM dose calculation and the dose-toxicity relationship.
Commonly used methods to calculate the RBM AD are the blood-based method, a
two-dimensional (2D) image-based method, or a combination of these two methods.
Although blood-based (or partially blood-based) dosimetry is an accepted method for
estimation of the RBM dose [1,3,7-9], the correlation with the observed hematological
toxicity is insufficient for clinical use [5,10]. Especially when the radiopharmaceutical
shows RBM retention, 2D image-based dosimetry seems to be a better predictor for
hematological toxicity than the blood-based method [5].
In our institution, both the abovementioned methods were prospectively applied in a
clinical phase I pretargeted RIT study in 20 patients with advanced colorectal cancer
[11]. Dosimetric data based on administration of a diagnostic 111In-labeled tracer were
used to predict blood-based and 2D image-based RBM AD in a subsequent treatment
with the same compound, but labeled with 177Lu. Although relatively low RBM absorbed
doses (<0.31 Gy) were predicted in several patients, RBM toxicity was observed. Accord-
ing to the NCI Common Terminology Criteria v3, five patients developed grade 1 to 2
thrombocytopenia and two patients developed grade 3 to 4 thrombocytopenia, and three
patients developed grade 1 to 2 leucopenia. Based on the applied dosimetry methods, no
dose limit based on the 177Lu dosimetry could be defined that distinguishes the patients
who showed toxicity from those without toxicity. Clearly, these calculations did not reli-
ably predict toxicity in this experimental treatment. This indicates that an improved dos-
imetry method leading to doses correlating with the RBM toxicity and probably in the
future use for prediction - and ideally prevention - of toxicity is desirable.
Furthermore, based on the data of the phase I study, it was suggested that treatment
with 90Y might improve the tumor-to-RBM dose ratio [11]. The half-life of 90Y (2.66
versus 6.71 days for 177Lu) better corresponds with the peptide residence time in the
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tumor [11] and therefore should lead to a higher tumor-to-RBM ratio. In addition, 90Y
is a well-known therapeutic radionuclide, e.g., as 90Y-ibritumomab tiuxetan (Zevalin®,
Bayer Schering Pharma AG, Berlin, Germany), an FDA-approved drug for treatment of
non-Hodgkin's lymphoma.
Assessment of the tumor-to-RBM dose ratio requires 3D dosimetry, since 2D
image-based tumor dosimetry does not lead to reliable results as a result of overpro-
jection with background tissue. Also, for the RBM dose calculation, 3D dosimetry is
preferred since it has been shown that single photon emission computed tomography
(SPECT)-based dosimetry leads to smaller errors than planar image-based dosimetry
[12]. This is mainly due to the lack of overprojecting organs and more accurate at-
tenuation correction.
Therefore, we hypothesized that 3D SPECT-based RBM dosimetry results better
correlate with bone marrow toxicity than the blood-based and 2D image-based
dosimetry results.
Recently, Boucek and Turner demonstrated a relationship between myelotoxicity and
RBM dose, calculated using a 3D image-based dosimetry method in 23 patients with
non-Hodgkin's lymphoma. They used a three-compartment model, comprising the
blood, whole body, and RBM activity, which was measured in the spine, pelvis, and
femur [13]. They calculated the RBM dose with a method relying on S-values, which
are calculated using idealized representative model-based anatomical phantoms [14].
The use of idealized model-based S-values for individual patient anatomy may not ac-
count for important differences between the model-based representation and the indi-
vidual patient anatomy. Such differences are particularly important in a therapeutic
setting. Schwartz et al. [4], who also used an S-value-based method, did not find a cor-
relation with toxicity. This emphasizes the potential importance of investigating dosim-
etry methods for RBM dosimetry that do not rely on idealized anatomical models and
that are more likely to give results that correlate with RBM toxicity.
In this study, we applied a method for 3D RBM dosimetry that does not depend on
S-values but instead uses Monte Carlo simulations for the dose calculation. For this
purpose, the 3D radiobiological dosimetry (3D-RD) software [15,16] was used in patients
who had undergone pretargeted RIT with a bispecific antibody and a 177Lu-labeled pep-
tide. The aims were (1) to accurately estimate the RBM dose and the tumor dose, (2) to
correlate the RBM dose with the RBM toxicity, and (3) to use the results for selection of
the most suitable radionuclide for this therapy.
Methods
Patients
Patients with metastatic colorectal cancer for whom no standard treatment was avail-
able were eligible for the pretargeted RIT study. The protocol (ClinicalTrials.gov Identi-
fier NCT00860860) was approved by the Regional Ethics Review Board (CMO).
Written confirmed consent was obtained from all patients prior to any study-related
procedures.
The patients received the anti-CEACAM5 × anti-hapten humanized trivalent bispeci-
fic antibody TF2. One day later, the 177Lu-labeled di-HSG peptide IMP288 (2.5 to
7.4 GBq) was administered as reported previously [11]. Of the 20 patients in this study,
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13 were eligible for the 3D image-based dosimetry as they had undergone a series of
four SPECT scans after administration of the 177Lu-labeled peptide.
Image acquisition and use in dosimetry
Anterior and posterior whole-body planar images were acquired immediately (at 8 cm/
min scan speed), at 3 h (6 cm/min), at 24 h, and at 72 h (both 4 cm/min) after administra-
tion of the 177Lu-labeled peptide, and followed by a SPECT scan involving continuous, cir-
cular scanning with a 180° scan arc, 64 views with both camera heads and 19 s/view. For
each patient, a region for the SPECT scanning was selected that contained the kidney re-
gion and at least one tumor lesion, as well as at least two lumbar vertebrae (LV).
A Siemens dual-head gamma camera (ECAM, Siemens Medical Soluations, Hoffman
Estates, IL, USA), equipped with medium-energy collimators was used with a symmet-
ric 15% window over the 208-keV energy peak for SPECT scanning and an additional
15% window over the 113-keV peak for the planar images.
The planar 177Lu images were only used to calculate the 177Lu RBM dose. Due to
overprojection of the background tissue, tumor dosimetry could not be performed on
planar images.
Subsequently, the SPECT scans were used for tumor and RBM dosimetry of the
177Lu dose. Simulation of 90Y doses was performed (matched pair dosimetry) for com-
parison with the 177Lu tumor-to-RBM dose ratios. For the 90Y simulation, the SPECT
images were rescaled to correct for the difference in half-life. Absorbed doses were cal-
culated relative to the administered activity.
A contrast-enhanced diagnostic computed tomography (CT) scan and a
fluorodeoxyglucose-positron emission tomography (FDG-PET)/CT (Biograph BGO
duo, Siemens Medical Solutions, Knoxville, TN, USA) in accordance with the
EANM guidelines were performed within 2 weeks prior to study entry, and for
follow-up, 8 weeks after 177Lu injection [17].
2D image- and blood-based red bone marrow dosimetry
During the pretargeted RIT study, the dose to RBM was calculated using a blood-based
[3] and a 2D image-based dosimetry method [18].
The blood-based RBM dose was based on blood samples collected 2 min, 30 min, 1 h,
2 h, 4 h, 24 h, and 72 h after peptide injection and on the total body activity (retrieved
from the whole-body planar images). The blood samples were counted in a gamma
counter (Wizard, Pharmacia-LKB, Uppsala, Sweden), using appropriate energy windows,
with reference samples prepared from the injected products. Whole-body activities were
calculated and combined with the blood counts for the final dose calculation as described
by Shen et al. [3]. This was performed with the SPRIND software [18] using an RBM-to-
blood activity concentration of 1, as was determined for 177Lu-peptide [19].
For the 2D image-based method, SPRIND was used to delineate the cranium, repre-
senting the activity in the RBM and to calculate the time-integrated activity coefficients.
The time-integrated activity coefficient of the cranium activity was divided by the frac-
tion of the RBM mass in the cranium to the RBM mass in the total skeleton, for which
the default value of 0.119 was taken from ICRP23's reference man. Subsequently,
OLINDA software [20] was used to calculate the RBM dose.
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SPECT image reconstruction
SPECT scans were reconstructed using the iterative reconstruction software ReSPECT
(Scivis, Göttingen, Germany), in six iterations, without noise reduction, with background
subtraction and attenuation correction using an attenuation coefficient of 0.13 cm−1,
based on the results of Brown et al. [21]. The algorithm uses attenuation correction with
constant attenuation coefficient within body contours estimated from photopeak and scat-
ter projections.
This implies that a correct body contour is needed for quantitative evaluation of the
images. In ReSPECT, the ‘threshold object background’ is used for definition of the
body contour; voxels with a value higher than this threshold are assigned to the body.
The contour can be defined correctly by the default threshold as long as the target
(body)-to-background activity ratio is high enough, which was the case for the first two
SPECT scans. For the third and fourth scans, the contour was fitted to the contour of
the first scan by lowering the threshold value, as the lower whole-body activity would
have led to a smaller body contour at the default settings. The comparison of body
contours of the early and later SPECT scans was performed with MATLAB (MathWorks,
Natick, MA, USA).
Calibration
To convert the pixel values in the SPECT images to activity (Bq), a calibration experi-
ment was performed. A cylindrical phantom was filled with 440 MBq 177Lu dissolved
in 9.1 L water and imaged using the same scanning and reconstruction protocol as used
for the patient SPECTs. The known activity at the time of acquisition, combined with
the number of counts in a volume drawn around the phantom, resulted in a calibration
factor of 6.23 × 10−6 MBq per count. In a separate calculation, we estimated the dead
time typically present in patient scans and in the phantom scan, using the equations
that hold for paralyzable system as described in Cherry et al. [22]. The observed values
based on quality control measurements of the SPECT camera, using the ‘two-source
method’, were in the order of 0.5 to 2 μs. This led to errors in activity concentrations at
a maximum of 1%. For this reason, we did not correct the images for the dead time.
Delineation and co-registration
Tumor-oriented co-registration of the SPECT and the low-dose CT images was per-
formed using the HERMES Gold 2.10 software (HERMES Medical Solutions, Stockholm,
Sweden). The co-registered CT images were cropped and scaled to the same matrix size
(128 × 128 × 78) and voxel dimensions (4,795 × 4.795 × 4.795 mm) as the SPECT images.
For each patient, VOIs were manually delineated in the LV (VOILV) on the SPECT images
for RBM dosimetry and for one tumor lesion (VOItumor) on the co-registered CT images
for the tumor dosimetry.
For the VOILV, at each time point, the RBM containing parts of at least two LV were
delineated and further processed as one VOI. If delineation on the SPECT image was
not possible because the LV could not be distinguished from the background, the co-
registered CT image was used for delineation.
Tumors were delineated on the rescaled CT by using a SPECT overlay. Occasionally,
after checking the VOIs on the PET images, the regions were changed so that FDG-
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positive areas of tumors that were SPECT-negative were included in the delineation be-
cause FDG-PET and SPECT images show different aspects of the pathophysiology.
Necrotic cores were included in the VOI, since these areas might still contain vital
tumor cells.
3D-RD
For the 3D dosimetry, the Monte Carlo-based 3D-RD dosimetry package - developed at
the Johns Hopkins Medical Institute (Baltimore, USA) - was used [16,23]. In this soft-
ware, the co-registered low-dose CT scan is used to assign a density value and compos-
ition (soft tissue, lung, or bone) to each voxel in the corresponding SPECT scans. The
density, composition, and the activity maps were the input for the Monte Carlo (MC)
simulations. For each SPECT scan, 106 MC simulations were run, using the spectra
probability distributions obtained from MIRD [24], resulting in a dose rate value per
voxel for each scan.
The dose per voxel was calculated by integrating the dose rates for each voxel, using
a hybrid trapezoidal-exponential fit consisting of linear fits between the first three time
points and an exponential tail obtained by fitting to the final two time points [25]. This
finally resulted in a dose map. The VOI mean absorbed doses were obtained by sum-
ming the deposited energy in the VOIs and integrating these resulting VOI dose rates.
For this integration, a similar fit as for the voxel doses was used.
3D tumor dosimetry
For the VOItumor, the mean absorbed dose (ADtumor) and a dose-volume histogram
(DVH) were calculated using 3D-RD. The DVH provides insight into the spatial dis-
tribution of AD in the tumor. For comparison with the ADtumor, the AD in the VOItu-
mor was also calculated using the sphere model as incorporated in OLINDA [20]. For
this purpose, the mass of the VOI was calculated using the density map created from
the low-dose CT and was used as the sphere mass as required by OLINDA. The
tumor time-integrated activity coefficient was calculated using the total activity in the
VOItumor at the four different time points, again using a similar hybrid trapezoidal-
exponential fit.
3D LV-based RBM dosimetry
The rigid co-registration as described above was tumor-oriented, and it was observed
that this did not lead to adequate co-registration of the LV, especially when slight differ-
ences in bending of the spine were observed. Therefore, delineation of the LV VOI was
performed on each SPECT image separately, precluding the ability to perform voxelized
dosimetry, and thus, only mean dose rates and mean absorbed doses were calculated
for the VOILV (ADRBM).
In addition to ADRBM, the biological effective dose (BEDRBM) was also calculated:
BEDRBM ¼ ADRBM 1þ G ∞ð Þ
α=β
ADRBM
 
ð1Þ
with α and β as the radiobiological parameters from the linear quadratic equation
model (α/β = 10 Gy [26]), AD as the absorbed dose, and G(∞) as the Lea-Catcheside
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G-factor expressing the reduction in cell kill as a result of sublethal damage repair dur-
ing treatment and which depends on the DNA repair rate (μ) = 0.46 h−1 [26].
The 3D LV-based ADRBM was compared to the blood-based and the 2D cranium-
based RBM dosimetry results and correlated with the grade of thrombocytopenia
(graded according to NCI Common Terminology Criteria v3), since thrombocytopenia
was the major toxicity experienced in this study.
Tumor-to-RBM dose ratios
In adequate treatment settings, the ADtumor should be sufficiently higher than the
ADRBM. To evaluate this, the tumor-to-RBM dose ratio ADtumor/ADRBM was calculated.
This calculation was done for the 177Lu dose and the simulated 90Y dose.
Results
Patients, VOIs, and RBM toxicity
Table 1 summarizes patient and VOI characteristics, the calculated mean tumor and
RBM doses, and the grades of thrombocytopenia and leucopenia, representing the se-
verity of the RBM toxicity. Patient numbers are the same as those used in the report of
the phase 1 study [11]. Figure 1 shows an example of a tumor lesion in the liver on CT,
SPECT, and PET images.
3D tumor doses
As shown in Table 1, the 177Lu ADtumor are 0.46 to 4.52 Gy. A typical DVH of a
tumor is shown in Figure 2. The ADtumor calculated with 3D-RD was systematically
greater than the OLINDA AD, although in most patients, the difference was small
Table 1 Patient and VOItumor details and dose results
Pt. # Age
(years)
Gender Location of
VOItumor
AA
(GBq)
Volume of
VOItumor (mL)
tox 3D-RD OLINDA
grade thr -
grade leuc
ADtumor
(Gy)
ADRBM
(Gy)
ADtumor
(Gy)
7 63 F Rectum 6.2 14 0 - 0 0.73 0.39 0.71
10 70 M Liver 7.4 70 4 - 1 2.94 0.51 2.67
11 55 F Liver 7.4 44 0 - 0 2.53 0.29 2.47
12 70 M Liver 7.4 386 0 - 0 1.54 0.30 1.47
13 76 M Colon 7.4 23 0 - 0 0.51 0.12 0.51
14 52 F Liver 4.0 23 1 - 0 3.70 0.70 3.72
15 58 M Liver 5.9 285 1 - 0 0.86 0.58 0.83
16 76 M Colon 4.6 121 3 - 2 0.66 0.97 0.64
17 73 M Lung 4.5 65 2 - 0 0.63 0.43 0.62
18 63 F Liver 2.5 104 0 - 2 4.52 0.47 4.44
19 66 F Liver 7.4 141 0 - 0 1.45 0.28 1.38
20 72 M Lung 5.6 723 1 - 0 0.46 0.72 0.45
21 39 F Liver 5.6 154 0 - 0 2.47 0.23 2.45
Mean 64 166 1.77 0.46 1.72
RBM = red bone marrow. AA = administered activity, Pt. # = patient number, tox = toxicity, grade thr = grade
thrombocytopenia, grade leuc = grade leucopenia.
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(difference <5.0%), except for one patient (number 10) who showed a 9.6% higher 3D-
RD tumor dose.
In all patients, the BED was just slightly higher than the AD with a maximum differ-
ence of 0.11%, which is expected due to the relatively low AD values.
Correlation between RBM dose and RBM toxicity
Figure 3 shows the blood-based, cranium-based, and 3D-RD-based RBM doses ver-
sus the grade of thrombocytopenia. 3D-RD-based RBM doses (Figure 3A) were
generally higher than the doses calculated with the blood-based and 2D image-
based methods (Figure 3B,C, respectively). The highest 3D-RD-based RBM dose
without thrombocytopenia and/or leucopenia was 0.39 Gy. The other patients
Figure 1 Metastases in the liver of patient 10 showing the lesions on CT (left), 177Lu-peptide
SPECT/CT (middle) and FDG-PET/CT (right). The arrow indicates the lesion that was used for the
tumor dosimetry.
Figure 2 Dose-volume histogram of the tumor volume of interest, located in the liver of patient 19.
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showed RBM toxicity and had RBM doses in the range of 0.42 to 0.97 Gy. There
was only one patient in this range (0.47 Gy) without thrombocytopenia, but this
patient had a grade 2 leucopenia.
As shown in Figure 3B,C, the blood-based and cranium-based methods do not separ-
ate patients with and without any grade of toxicity. Based on the blood-based RBM
dose, only patients with grade 3 to 4 thrombocytopenia could be distinguished (0.51
and 0.66 Gy) from the other patients (0.14 to 0.29 Gy). For the cranium-based dosim-
etry, the patient with grade 4 thrombocytopenia was the only patient with toxicity who
showed a dose outside the AD range of the patients without toxicity (0.34 versus 0.11
to 0.26 Gy for the others).
Some patients showed accumulation of activity in the RBM (see Figure 4), leading to
a higher RBM dose.
Figure 3 3D-RD-based (A), blood-based (B), and 2D cranium-based (C) absorbed dose in the red
bone marrow versus the grade of platelet toxicity. AD RBM = absorbed dose red bone marrow.
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Tumor-to-RBM dose ratios for 177Lu compared to 90Y
The effect of 90Y versus 177Lu was shown by the simulated 90Y dosimetry (see Table 2).
The mean increase in the tumor-to-RBM dose ratio is 25% when using 90Y instead of
177Lu, and the mean ratio for the group changed from 4.68 for 177Lu to 5.41 for 90Y.
Interestingly, patients with a high RBM dose in 177Lu treatment showed the largest
percentage increase in the tumor-to-RBM dose ratio when changing to 90Y (Figure 5).
Discussion
In this study, we demonstrated the utility of 3D-RD for tumor and RBM dose calcula-
tion and the correlation with RBM toxicity.
Using 3D-RD, all patients with RBM toxicity had a higher RBM dose than the pa-
tients without any RBM toxicity. In contrast, this was not observed with the conven-
tional blood-based and 2D cranium-based methods which might be caused by an
underestimation of the calculated doses.
RBM doses were in most patients higher when calculated with 3D-RD than those
with the blood-based method (11/13 patients) and the cranium-based method (12/13
patients). In the blood-based RBM dosimetry used, it was assumed that the blood activ-
ity concentration is proportional to the RBM concentration at all time points. In most
patients, we clearly observed RBM retention at the later imaging time points (24 and
72 h post injection). Therefore, at least in these patients, the blood-based method will
result in an underestimation for the ADRBM and therefore in a poorer correlation with
the RBM toxicity, compared to the 3D-RD result.
The 2D cranium-based dosimetry might also have resulted in an underestimation
of the ADRBM. The fraction of RBM in the cranium is used to represent the activ-
ity in the total RBM. In the SPRIND software package, this fraction was defined as
0.119, based on the ICRP23's reference man, representing a 40-year-old male. As
the median age of our patient population was 63 years, this fraction might have
Figure 4 Accumulation of activity in the RBM. (Left) The sagittal cross section of low-dose CT and the
SPECT image made at 72 h after administration of the 177Lu-peptide of patient 20. (Right) The SPECT and
low-dose CT images of vertebrae in which activity accumulated.
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been an overestimation. Since the distribution of the RBM over the skeleton is
both age- and patient-specific, ideally, this fraction should be individually mea-
sured, and a patient-specific percentage of the RBM in a certain VOI should be
used for this method.
For both methods, a patient-specific difference in the severity of the underestimation
might explain the relative difference between the methods in relation to the observed
RBM toxicity.
In addition, the difference between the 3D LV-based and 2D cranium-based ADRBM
could be explained by inhomogeneous uptake in the RBM [2] and the influence of ac-
tivity surrounding the LV on the ADLV. Taking this into account, the 3D image-based
results seem to be more accurate by avoiding the influence of overlapping organs and
Table 2 The difference between ADtumor/ADRBM for treatment with
177Lu and 90Y
Patient number Ratio tumor/RBM dose Percentage difference
177Lu 90Y
7 1.88 2.13 13%
10 5.72 6.54 14%
11 8.84 9.78 11%
12 5.08 7.27 43%
13 4.33 4.33 0%
14 5.26 6.37 21%
15 1.49 2.29 54%
16 0.68 1.06 56%
17 1.46 2.02 39%
18 9.45 8.87 −6%
19 5.11 4.97 −3%
20 0.64 0.99 54%
21 10.91 13.72 26%
A positive difference represents a higher tumor-to-RBM dose ratio in 90Y, and the percentage is calculated compared to
the 177Lu ratio. RBM = red bone marrow.
Figure 5 Red bone marrow (RBM) dose versus the percentage difference in ADtumor/ADRBM for
90Y
compared to 177Lu. A positive difference represents a higher tumor-to-RBM dose ratio in 90Y.
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due to more accurate VOI drawing because the target-to-background ratio is higher for
3D than that for 2D.
Figure 3A suggests that RBM toxicity can be expected for RBM doses higher
than 0.4 Gy. As in all dosimetry studies, the absolute value (i.e., 0.4 Gy) is highly
influenced by methodological choices such as not to correct for the partial volume
effect. This might partially explain the difference with the general rule that a blood
(and RBM dose) of 2 Gy is considered to be safe [6,27,28]. Also, and probably
most important, all patients had a history of multiple lines of polychemotherapy,
which most certainly negatively affected bone marrow reserves and thus myelotoxi-
city [29].
For actual definition of a threshold, a larger study, including patient groups with and
without previous chemotherapy, should be performed.
In this study, attenuation correction was performed using a method that assumes a
homogeneous body density and therefore overestimates the attenuation in low-density
tissue like the lungs. To avoid this, CT-based attenuation correction would be preferred
for future studies. Unfortunately, there was no SPECT-CT available at our department
during this clinical study that was finished in 2011.
In our view, the absorbed dose - or a derived parameter of the AD (i.e., BED) - has
the potential to be predictive for different radiolabeled therapeutics, irrespective of the
radionuclides, radiolabeled peptides, radiolabeled antibodies, or pretargeting. As we
have shown, 3D image-based dosimetry seems to result in a clear dose-toxicity relation-
ship and therefore might be a valuable approach for the calculation of a maximally tol-
erated absorbed dose (MTAD). However, a robust definition of a reliable MTAD based
on this method would require processing of larger datasets.
The OLINDA-based results of the tumor-absorbed doses were comparable to the
3D-RD results and are in accordance with previous research [30]. In general, the
OLINDA sphere model led to a somewhat lower dose. This could be explained by the
influence of activity surrounding the VOI. For the use of the OLINDA sphere model,
the VOI is assumed to be isolated. In 3D-RD, the surrounding activity does contribute
to the tumor dose, which is more realistic. Nevertheless, we conclude that OLINDA
provides a fast and practical method for tumor dosimetry.
OLINDA RBM dosimetry, or more generally S-value-based RBM dosimetry, is not
feasible without a known (or a model-based) RBM mass. Using a dose point kernel as
alternative for the MC-simulation would reduce the time needed for the calculation.
Nevertheless, 3D-RD can easily provide dose rates per time point and enables delinea-
tion for each time point. Therefore, for the calculation of the bone marrow dose, we
prefer 3D-RD and we consider MC-based software advantageous for RBM dosimetry,
despite the fact that it is more time-consuming.
Matched pair dosimetry, as shown for 177Lu and 90Y, proved to be a convenient and
inexpensive method (compared to animal or patient studies) for exploring the effect
of the different radionuclide on the tumor-to-RBM dose ratio. The results of the 90Y
simulation confirm the hypothesis that replacing 177Lu by 90Y would lead to an in-
crease in the tumor-to-RBM dose ratio, especially in patients given a higher RBM
dose. In such patients, we see a relatively slow, but clear, accumulation of activity in
the RBM, which is most visible on the later scans. Therefore, the shorter half-life of
90Y is advantageous.
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Conclusions
3D-RD-based RBM dosimetry is feasible and a more sensitive predictor for selection of
patients showing any grade of RBM toxicity than blood-based and planar image-based
RBM doses. In addition, comparing the 177Lu tumor-to-RBM dose ratios with the simu-
lated 90Y ratios proved to be a useful method to explore the effect of using a different
radionuclide for this therapeutic modality.
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